Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis-Reference-Cited by-同舟云学术

Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis

Published:2018-04-04 Issue:7 Volume:2 Page:777-786
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

M. F. Silva Juliana¹,Ladomenou Fani¹,Carpenter Ben²,Chandra Sharat³⁴,Sedlacek Petr⁵,Formankova Renata⁵,Grandage Vicky²,Friswell Mark⁶⁷,Cant Andrew J.⁶⁷,Nademi Zohreh⁶⁷,Slatter Mary A.⁶⁷,Gennery Andrew R.⁶⁷,Hambleton Sophie⁶⁷,Flood Terence J.⁶⁷,Lucchini Giovanna¹,Chiesa Robert¹,Rao Kanchan¹,Amrolia Persis J.¹,Brogan Paul⁸,Wedderburn Lucy R.⁸⁹,Glanville Julie M.¹,Hough Rachael²,Marsh Rebecca³⁴,Abinun Mario⁶⁷,Veys Paul¹

Affiliation:

1. Department of BMT, Great Ormond Street Hospital for Children, National Health Service (NHS) Foundation Trust, London, United Kingdom;

2. Department of Adolescent BMT, University College Hospital, NHS Foundation Trust, London, United Kingdom;

3. Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;

4. Department of Pediatrics, University of Cincinnati, Cincinnati, OH;

5. Department of Pediatric Hematology and Oncology, Teaching Hospital Motol, Prague, Czech Republic;

6. Great North Children’s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom;

7. Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom;

8. Department of Rheumatology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom; and

9. University College London Great Ormond Street Institute of Child Health and NIHR GOSH Biomedical Research Centre, NHS Trust, London, United Kingdom

Abstract

Key Points Allo-HSCT using reduced intensity conditioning with alemtuzumab appears to be effective and safe for patients with refractory JIA. Early allo-HSCT may prevent joint damage, reduce toxicity associated with immunosuppression, and reduce transplant-related mortality.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/7/777/880647/advances014449.pdf

Reference50 articles.

1. Pathogenesis of systemic inflammatory diseases in childhood: “Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome”;Yokota;Mod Rheumatol,2015

2. Diagnosis and classification of juvenile idiopathic arthritis;Eisenstein;J Autoimmun,2014

4. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis;Minoia;J Rheumatol,2015

5. Infections in children treated with biological agents;Woerner;Pediatr Infect Dis J,2013

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy: more difficult to diagnose, not to control?;Rheumatology;2024-05-11

2. French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases;La Revue de Médecine Interne;2024-02

3. Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe;Pediatric Rheumatology;2024-01-05

4. A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis;Expert Review of Clinical Immunology;2024-01

5. Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis;Advances in Experimental Medicine and Biology;2024